Pistiolis Leda, Alawieh Sahar, Halldorsdottir Thorhildur, Kovács Anikó, Olofsson Bagge Roger
Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.
Department of Surgery, Sahlgrenska University Hospital Gothenburg, 41345 Gothenburg, Sweden.
Biomolecules. 2025 Apr 15;15(4):581. doi: 10.3390/biom15040581.
Laboratory and animal studies indicate that melatonin exerts a negative impact on breast cancer progression and metastasis. These actions are both receptor-dependent and -independent. Of the two transmembrane melatonin receptors identified in humans, breast cancer expresses only MT1. The aim of this study was to investigate the expression of MT1 in hormone-receptor-positive, HER2-negative invasive ductal breast carcinoma in postmenopausal women and its possible correlations with clinicopathological parameters and survival. A total of 118 patients with luminal A/B primary breast cancer with or without axillary metastases were identified. The MT1 receptor expression was immunohistochemically assessed as a percentage of stained cells and a weighted index (WI) (percentage multiplied by staining intensity). Most tumor samples (84.7%) and metastasized lymph nodes (96%) stained positive for MT1, with varying intensity. No statistically significant correlations were found between the MT1 expression or the WI in the primary tumor and the patient and tumor characteristics, or the MT1 and WI in the metastasized lymph nodes. The survival analysis did not reveal a significant effect of MT1 expression or the WI on the risk of recurrence or survival.
实验室和动物研究表明，褪黑素对乳腺癌的进展和转移有负面影响。这些作用既依赖受体，也不依赖受体。在人类中鉴定出的两种跨膜褪黑素受体中，乳腺癌仅表达MT1。本研究的目的是调查绝经后女性激素受体阳性、HER2阴性浸润性导管乳腺癌中MT1的表达情况，及其与临床病理参数和生存率的可能相关性。共确定了118例伴有或不伴有腋窝转移的luminal A/B原发性乳腺癌患者。通过免疫组织化学评估MT1受体表达，以染色细胞的百分比和加权指数（WI）（百分比乘以染色强度）来表示。大多数肿瘤样本（84.7%）和转移淋巴结（96%）MT1染色呈阳性，强度各异。在原发性肿瘤中，MT1表达或WI与患者及肿瘤特征之间，以及转移淋巴结中的MT1和WI之间，均未发现统计学上的显著相关性。生存分析未显示MT1表达或WI对复发风险或生存率有显著影响。
